<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01676805</url>
  </required_header>
  <id_info>
    <org_study_id>120193</org_study_id>
    <secondary_id>12-C-0193</secondary_id>
    <nct_id>NCT01676805</nct_id>
  </id_info>
  <brief_title>Tissue Collection for Studies of Lymph Cancer</brief_title>
  <official_title>Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:

      - Lab studies help researchers better understand cancer biology. This information may lead to
      new methods for diagnosing or treating cancer. To develop these studies, researchers want to
      collect samples from people with cancer or precancer conditions of the lymph system. These
      conditions include multiple myeloma, different types of lymphoma, and adult
      leukemia/lymphoma. The samples collected will include blood, urine, bone marrow, and tumor
      and skin tissue.

      Objectives:

      - To collect tissue samples to study different types of lymph cancer.

      Eligibility:

      - Individuals at least 18 years of age who have a lymphoid cancer or precancer condition.

      Design:

        -  Participants will be screened with a physical exam and medical history.

        -  Different samples will be collected for study. Blood samples will be collected at the
           initial testing. More blood samples will be collected at different treatment points.
           Other liquid samples include urine, bone marrow, and any abnormal fluid. Tumor tissue
           and skin tissue biopsies will also be collected for study.

        -  Treatment will not be provided as part of this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      An estimated 79,190 people living in the United States will be diagnosed with lymphoma in
      2012, including 9,060 cases of HL, 70,130 cases of non-Hodgkin s lymphoma (NHL) and multiple
      cases of adult T-cell leukemia/lymphoma. Laboratory investigations conducted in the Lymphoid
      Malignancies Branch, including analysis of cellular, molecular, genetic and genomic biology
      are attempting to develop new prognostic and diagnostic models, therapeutic agents and novel
      treatment approaches for lymphoid malignancies and pre-malignant conditions.

      Objectives:

      This biology protocol is designed to allow sample acquisition for use in the study of
      lymphoid malignancies and malignancy precursors, including but not limited to B and T cell
      malignancies, such as diffuse large B-cell lymphoma (DLBCL), Hodgkin s lymphoma (HL),
      multiple myeloma (MM), lymphomatoid granulomatosis (LYG) and adult T-cell leukemia/lymphoma
      (ATL). A variety of laboratory investigations will be conducted on blood, tumor, bone marrow,
      urine, abnormal fluid and normal tissue, including analysis of cellular, molecular, genetic
      and genomic biology in the support of NIH translational trials to develop new therapeutic
      agents and novel treatment approaches as well as new prognostic and diagnostic models.

      Eligibility:

      Adult patients with confirmed pathological diagnosis of lymphoid malignancy or lymphoid
      precursor, including B-cell and T-cell lymphomas: including but not limited to diffuse large
      B-cell lymphoma (DLBCL), Hodgkin s lymphoma (HL), multiple myeloma (MM), lymphomatoid
      granulomatosis (LYG) and adult T-cell leukemia/lymphoma (ATL).

      Design:

      The purpose of this study is to examine, in an exploratory fashion, a variety of biologic
      assays relevant to the investigation of lymphoid malignancies.

      It is anticipated that up to 60 consented subjects will be studied each year. Thus, an
      accrual ceiling of 600 consented subjects is planned over 10 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 21, 2012</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sample Acquisition</measure>
    <time_frame>Ongoing</time_frame>
    <description>Standard exploratory and descriptive statistical methods will be used, as appropriate to the specific biologic assay. Any findings will be reported in the context of this exploratory study, with appropriatecaveats.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Hodgkin Disease</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Lymphomatoid Granulomatosis</condition>
  <condition>Leukemia-Lymphoma, Adult T-Cell</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Known lymphoid malignancy or precursor disease to a lymphoid malignancy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Primary clinical patients seen for a known lymphoid malignancy or precursor disease to a
        lymphoid malignancy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  Patients with known lymphoid malignancy or precursor disease to a lymphoid malignancy,
             including multiple myeloma, B-cell and T-cell lymphomas: including but not limited to
             diffuse large B-cell lymphoma (DLBCL), Hodgkin s lymphoma (HL), multiple myeloma (MM),
             lymphomatoid granulomatosis (LYG) and adult T-cell leukemia/lymphoma (ATL).

          -  Confirmation of pathological diagnosis.

             --Confirmation of diagnosis is required from the Laboratory of Pathology, NCI. Tumor
             tissue that has been previously collected and is available for study or that can be
             collected with minimal additional risk to the subject during sampling required for
             routine patient care or required testing on an NIH research protocol will be used for
             diagnosis.

          -  Greater than or equal to 18 years of age.

          -  ECOG performance 0-2.

          -  Must be willing and able to provide informed consent.

        INCLUSION FOR APHERESIS:

          -  Hemoglobin greater than or equal to 10 mg/dL and platelet count greater than 75 K/uL.

          -  Weight greater than 25 kilograms

          -  HIV negative

          -  Prothrombin Time - within normal limits

          -  Partial Thromboplastin Time - within normal limits

          -  Medically indicated central line in place or adequate peripheral venous access

        EXCLUSION CRITERIA:

          -  Pregnant or breast feeding women will not be eligible for any aspect of this protocol
             except phlebotomy.

          -  Active symptomatic major organ disorder that would increase the risk of biopsy or
             apheresis, including but not limited to ischemic heart disease, recent myocardial
             infarction, active congestive heart failure, pulmonary dysfunction.

          -  Active concomitant medical or psychological illnesses that may increase the risk to
             the subject or inability to obtain informed consent, at the discretion of the
             principal investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark J Roschewski, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret Shovlin, R.N.</last_name>
    <phone>(866) 820-4505</phone>
    <email>mshovlin@mail.nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark J Roschewski, M.D.</last_name>
    <phone>(240) 760-6183</phone>
    <email>mark.roschewski@nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact National Cancer Institute Referral Office</last_name>
      <phone>888-624-1937</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Jamaica</country>
  </removed_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2012-C-0193.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, LÃ³pez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jun 20;346(25):1937-47.</citation>
    <PMID>12075054</PMID>
  </reference>
  <reference>
    <citation>Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010 Apr 15;362(15):1417-29. doi: 10.1056/NEJMra0807082. Review.</citation>
    <PMID>20393178</PMID>
  </reference>
  <reference>
    <citation>Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel R, Grogan TM, Fisher RI, Miller TP, LeBlanc M, Chiorazzi M, Zhao H, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Staudt LM. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003 Sep 15;198(6):851-62.</citation>
    <PMID>12975453</PMID>
  </reference>
  <verification_date>January 3, 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2012</study_first_submitted>
  <study_first_submitted_qc>August 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2012</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Developing Novel Treatment Approaches</keyword>
  <keyword>Developing Therapeutic Agents</keyword>
  <keyword>Analysis of Genetic and Genomic Biology</keyword>
  <keyword>New Prognostic and Diagnostic Models</keyword>
  <keyword>Analysis of Cellular and Molecular Biology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphomatoid Granulomatosis</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

